Colorado Governor John Hickenlooper signed into law HB 1307, legislation prohibiting the sale of over-the-counter (OTC) medicines containing the cough suppressant dextromethorphan (DXM) to minors.
CHPA is pleased to provide comments on behalf of our members in response to the notice regarding the “acts, policies, and practices of China determined to be unreasonable or discriminatory and to burden or restrict U.S. commerce.”
We are encouraged by the ongoing, bipartisan momentum behind this reform and look forward to seeing the legislation move forward in the House as well as the Senate.
Overwhelming scientific evidence shows that excess sun exposure without sunscreen increases the risk of developing skin cancer. Banning key ingredients in effective sunscreens will unnecessarily reduce the selection of safe and effective sunscreen products available.
Today, the United States Senate Health, Education, Labor and Pensions (HELP) Committee approved S. 2315, the Over-the-Counter Drug Safety, Innovation, and Reform Act by a 22-1 vote.
CHPA thanks Governor Walker for signing this important bill into law as well as Senator Stroebel and Representative Kremer for their leadership and commitment to passing legislation aimed at addressing the issue of teen OTC cough medicine abuse
CHPA released the following statement today by President and CEO, Scott Melville, applauding the introduction of The Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018
CHPA welcomes the opportunity to comment on Nicotine Replacement Therapies (NRT). A number of our member companies hold new drug applications or abbreviated new drug applications for NRT. As such, we have an interest in the subject matter of FDA’s notice.
The 2017 results from the National Institute on Drug Abuse and University of Michigan’s annual drug abuse survey were released today showing that the percentage of teens using OTC cough medicine containing DXM to get high remains at just three percent, the lowest level recorded since 2015.
CHPA appreciates that FDA has taken the time to review the data associated with certain isolated or synthetic carbohydrates not listed as a dietary fiber and looks forward to engaging with FDA in efforts to clarify and improve the regulation of all dietary supplements.
